Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates

Journal of Proteome Research

Volumn 6, Issue 7, 2007, Pages 2833-2840

  Dalrymple, Annette ^a   Wild, Edward J ^b   Joubert, Richard ^a   Sathasivam, Kirupa ^c   Björkqvist, Maria ^a,d   Petersén, Åsa ^a,d   Jackson, Graham S ^b   Isaacs, Jeremy D ^b   Kristiansen, Mark ^b   Bates, Gillian P ^c   Leavitt, Blair R ^e   Keir, Geoff ^f   Ward, Malcolm ^a   Tabrizi, Sarah J ^b,f  

^a Proteome Sciences plc   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d LUND UNIVERSITY   (Sweden)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

2D electrophoresis; Biomarkers; ELISA; Huntington's disease; LC MS MS; MALDI TOF; Neuroinflammation; Plasma; Proteomics

Indexed keywords

APOLIPOPROTEIN A4; BETA ACTIN; BIOLOGICAL MARKER; CLUSTERIN; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUNTINGTON CHOREA; IMMUNOBLOTTING; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MOUSE; NEURITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

MUS;

EID: 34547167008     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr0700753     Document Type: Article

References (37)

1. Huntington's Disease, 3rd ed.; Bates, G., Harper P. S., Jones L., Eds.; Oxford University Press: Oxford, 2002.
2. Bjorkqvist, M.; Petersen, A.; Bacos, K.; Isaacs, J.; Norlen, P.; Gil, J.; Popovic, N.; Sundler, F.; Bates, G. P.; Tabrizi, S. J., et al. Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Hum. Mol. Genet. 2006, 15, 1713-1721.
3. Leblhuber, F.; Walli, J.; Jellinger, K.; Tilz, G. P.; Widner, B.; Laccone, F.; Fuchs, D. Activated immune system in patients with Huntington's disease. Clin. Chem. Lab. Med. 1998, 36, 747-750.
4. The Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov. Disord. 1996, 11, 136-142.
5. Handley, O. J.; Naji, J. J.; Dunnett, S. B.; Rosser, A. E. Pharmaceutical, cellular and genetic therapies for Huntington's disease. Clin. Sci. 2006, 110, 73-88.
6. Henley, S. M.; Bates, G. P.; Tabrizi, S. J. Biomarkers for neurodegenerative diseases. Curr. Opin. Neurol. 2005, 18, 698-705.
7. Hersch, S. M.; Gevorkian, S.; Marder, K.; Moskowitz, C.; Feigin, A.; Cox, M.; Como, P.; Zimmerman, C.; Lin, M.; Zhang, L., et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG. Neurology 2006, 66, 250-252.
8. Borovecki, F.; Lovrecic, L.; Zhou, J.; Jeong, H.; Then, F.; Rosas, H. D.; Hersch, S. M.; Hogarth, P.; Bouzou, B.; Jensen, R. V., et al. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 11023-11028.
9. Zabel, C.; Chamrad, D. C.; Priller, J.; Woodman, B.; Meyer, H. E.; Bates, G. P.; Hose, J. Alterations in the Mouse and Human Proteome Caused by Huntington's Disease. Mol. Cell. Proteomics 2002, 1, 366-375.
10. Shoulson, I. Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 1981, 31, 1333-1335.
11. Boyum, A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand. J. Clin. Lab. Invest. Suppl. 1968, 97, 77-89.
12. Weekes, J.; Wheeler, C. H.; Yan, J. X.; Weil, J.; Eschenhagen, T.; Scholtysik, G.; Dunn, M. J. Bovine dilated cardiomyopathy: proteomic analysis of an animal model of human dilated cardiomyopathy. Electrophoresis 1999, 20, 898-906.
13. Heinke, M. Y.; Wheeler, C. H.; Yan, J. X.; Amin, V.; Chang, D.; Einstein, R.; Dunn, M. J.; dos Remedios, C. G. Changes in myocardial protein expression in pacing-induced canine heart failure. Electrophoresis 1999, 20, 2086-2093.
14. Standen, C. L.; Perkinton, M. S.; Byers, H. L.; Kesavapany, S.; Lau, K. F.; Ward, M.; McLoughlin, D.; Miller, C. C. The neuronal adaptor protein Fe65 is phosphorylated by mitogen-activated protein kinase (ERK1/2). Mol. Cell. Neurosci. 2003, 24, 851-857.
15. Joubert, R.; Strub, J. M.; Zugmeyer, S.; Kobi, D.; Carte, N.; Van Dorsselaer, A.; Boucherie, H.; Jaquet-Guffreund, L. Identification by mass spectrometry of two-dimensional gel electrophoresis-separated proteins extracted from lager brewing yeast. Electrophoresis 2001, 22, 2969-2982.
16. Q150/Q150 knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res. Bull. 2007, 72, 83-97.
17. Hockly, E.; Woodman, B.; Mahal, A.; Lewis, C. M.; Bates, G. Standardization and statistical approaches to therapeutic trials in the R6/2 mouse. Brain Res. Bull. 2003, 61, 469-479.
18. Han, M. Cytokines and the hepatic acute phase response. J. Pathol. 1997, 181, 257-266.
19. Choi-Miura, N.-H.; Oda, T. Relationship between multifunctional protein clusterin and Alzheimer disease. Neurobiol. Aging 1996, 17, 717-722.
20. Jones, S. E.; Jomary, C. Clusterin. Int. J. Biochem. Cell Biol. 2002, 34, 427-431.
21. Cancello, R.; Tounian, A.; Poitou, C.; Clement, K. Adiposity signals, genetic and body weight regulation in humans. Diabetes Metab. 2004, 30, 215-227.
22. Perlstein, R. S.; Mougey, E. H.; Jackson, W. E.; Neta, R. Interleukin-1 and interleukin-6 act synergistically to stimulate the release of adrenocorticotropic hormone in vivo. Lymphokine Cytokine Res. 1991, 10, 141-146.
23. Sanberg, P. R.; Fibiger, H. C.; Mark, R. F. Body weight and dietary factors in Huntington's disease patients compared with matched controls. Med. J. Aust. 1981, 1, 407-409.
24. Gasque, P.; Dean, Y. D.; McGreal, E. P.; VanBeek, J.; Morgan, B. P. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 2000, 49, 171-186.
25. Xiong, Z.-Q.; Qian, W.; Suzuki, K.; McNamara, J. O. Formation of complement membrane attack complex in mammalian cerebral cortex evokes seizures and neurodegeneration. J. Neurosci. 2003, 23, 955-960.
26. Pavese, N.; Gerhard, A.; Tai, Y. F.; Ho, A. K.; Turkheimer, F.; Barker, R. A.; Brooks, D. J.; Piccini, P. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 2006, 66, 1638-1643.
27. Tai, Y.; Pavese, N.; Gerhard, A.; Tabrizi, S.; Barker, R.; Brooks, D.; Piccini, P. Microglial activation in presymptomatic Huntington's disease gene carriers: a combined C-11-PK11195 and C-11-raclopride PET study. Neurology 2006, 66, A134.
28. Hodges, A.; Strand, A. D.; Aragaki, A. K.; Kuhn, A.; Sengstag, T.; Hughes, G.; Elliston, L. A.; Hartog, C.; Goldstein, D. R.; Thu, D., et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet. 2006, 15, 965-977.
29. Duguid, J. R.; Bohmont, C. W.; Liu, N.; Tourtellotte, W. W. Changes in Brain Gene Expression Shared by Scrapie and Alzheimer Disease. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 7260-7264.
30. Nilselid, A. M.; Davidsson, P.; Nagga, K.; Andreasen, N.; Fredman, P.; Blennow, K. Clusterin in cerebrospinal fluid: Analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem. Int. 2006, 48, 718-728.
31. Du, Y.; Bales, K. R.; Dodel, R. C.; Liu, X.; Glinn, M. A.; Horn, J. W.; Little, S. P.; Paul, S. M. Alpha 2-macroglobulin attenuates beta-amyloid peptide 1-40 fibril formation and associated neurotoxicity of cultured fetal rat cortical neurons. J. Neurochem. 1998, 70, 1182-1188.
32. Narita, M.; Holtzman, D. M.; Schwartz, A. L.; Bu, G. Alpha 2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J. Neurochem. 1997, 69, 1904-1911.
33. Gutekunst, C.-A.; Li, S.-H.; Yi, H.; Mulroy, J. S.; Kuemmerle, S.; Jones, R.; Rye, D.; Ferrante, R. J.; Hersch, S. M.; Li, X.-J. Nuclear and Neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 1999, 19, 2522-2534.
34. Borth, W. Alpha 2-macroglobulin, a multifunctional binding protein with targeting characteristics. FASEB J. 1992, 6, 3345-3353.
35. Hye, A.; Lynham, S.; Thambisetty, M.; Causevic, M.; Campbell, J.; Byers, H. L.; Hooper, C.; Rijsdijk, F.; Tabrizi, S. J.; Banner, S., et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 2006, 129, 3042-3050.
36. Campbell, S. J.; Finlay, M.; Clements, J. M.; Wells, G.; Miller, K. M.; Perry, V. H.; Anthony, D. C. Reduction of excitotoxicity and associated leukocyte recruitment by a broad-spectrum matrix metalloproteinase inhibitor. J. Neurochem. 2004, 89, 1378-1386.
37. Heiser, M.; Hutter-Paier, B.; Jerkovic, L.; Pfragner, R.; Windisch, M.; Becker-Andre, M.; Dieplinger, H. Vitamin E binding protein afamin protects neuronal cells in vitro. J. Neural Transm. Suppl. 2002, 337-345.